This module features an experts review of the risk factors for breast cancer recurrence current guidelines for the use of biomarkers in treatment decisionmaking for patients with early breast cancer and approaches for the individualization of adjuvant therapy for patients with HRpositiveHER2negative highrisk early breast cancer
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/role-of-cdk46-inhibitors-in-hrher2-ebc/29233-73963
- Start Date: 2025-01-24 06:00:00
- End Date: 2025-01-24 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Lilly (Any division) - Amount: 55901.25 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest